您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Tautomycin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tautomycin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tautomycin图片
CAS NO:109946-35-2
包装:25μg
市场价:4820元

产品介绍
Tautomycin是可从Streptomycesverticillatus中分离得到的一种真菌类抗生素,是蛋白磷酸酶1和2A的有效特异性抑制剂,在没有Ca2+的情况下诱导平滑肌收缩,Kiapp值分别为0.16nM和0.4nM。
Cas No.109946-35-2
别名互变霉素
Canonical SMILESC[C@@H]([C@]([C@H](CC1)C)([H])O[C@@]1(CC[C@H]2C)O[C@H]2CC[C@H](C)C(C)=O)CC[C@H](O)[C@H](C)C(C[C@@H](O)[C@H](OC)[C@@H](C(C)C)OC(C[C@H](C(C(O3)=O)=C(C3=O)C)O)=O)=O
分子式C41H66O13
分子量766.96
溶解度Soluble in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Tautomycin, an antifungal antibiotic isolated from the bacterium Streptomyces verticillatus, is a potent and specific inhibitor of protein phosphatases 1 and 2A and induces contraction of smooth muscle under Ca2+-free conditions, with Kiapp values of 0.16 nM and 0.4 nM for PP1 and PP2A, respectively[1][2].

MTC cell growth is inhibited in a dose-dependent manner by Tautomycin (0-1000 nM, 48 hours)[2].NE markers ASCL1 and CgA in human MTC cells are decreased in a dose-dependent manner by Tautomycin (0-1000 nM, 48 hours)[2].|| Cell Proliferation Assay[2]||Cell Line:|Human MTC cells|Concentration:|0-1000 nM|Incubation Time:|48 hours|Result:|Inhibited MTC cell growth in a dose-dependent manner.|| Western Blot Analysis[2]||Cell Line:|Human MTC cells|Concentration:|0-1000 nM|Incubation Time:|48 hours|Result:|Led to a dose-dependent decrease in the NE markers ASCL1 and CgA.

[1]. MacKintosh C, et al. Tautomycin from the bacterium Streptomyces verticillatus. Another potent and specific inhibitor of protein phosphatases 1 and 2A. FEBS Lett. 1990 Dec 17;277(1-2):137-40. [2]. Adler JT, et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther. 2009 Apr;8(4):914-20.